A pH-sensitive peptide amphiphilic-based drug delivery system inhibits hepatocellular carcinoma growth by suppressing hepatic stellate cell activation
Source abstract
Abstract
Chemotherapy is crucial for treating intermediate and advanced hepatocellular carcinoma (HCC). However, anthracycline agents such as doxorubicin (DOX) are often expelled from tumor cells by P-glycoprotein (P-gp), which decreases the intracellular drug levels and leads to treatment failure. Activated hepatic stellate cells (aHSCs) are critical in liver fibrosis and HCC progression and facilitate liver cancer development. Importantly, liver fibrosis progression is closely linked to the expression of cyclooxygenase-2 (COX-2). Here, we developed a pH-responsive peptide drug delivery system, Pep loaded with DOX and CXB (DC/Pep), which targets HCC by transporting the COX-2 inhibitor celecoxib (CXB) alongside the conventional chemotherapeutic drug DOX. DC/Pep transitioned from spherical particles to high aspect ratio aggregates in a mildly acidic environment, delaying chemotherapeutic agent efflux from the tumor. DC/Pep effectively inhibited hepatic stellate cell activation and reduced collagen fiber synthesis, thereby preventing the development of liver fibrosis. Consequently, the proliferation of ectopic and orthotopic HCC tumors was effectively inhibited, leading to an enhanced antitumor effect. This study is important for designing novel drug delivery systems using peptide amphiphiles for the treatment of intermediate and advanced HCC.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Liver physiology and pathology · Peptidase Inhibition and Analysis · Neuropeptides and Animal Physiology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21834 ↗
2. Targeted and immune-based Therapies for hepatocellular carcinoma10.1053/j.gastro.2018.09.051 ↗
3. Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy10.7150/thno.71693 ↗
4. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma10.1053/j.gastro.2013.01.002 ↗
5. Activated hepatic stellate cells: negative regulators of hepatocyte proliferation in liver diseases10.1002/hep.25761 ↗
6. HK1 from hepatic stellate cell–derived extracellular vesicles promotes progression of hepatocellular carcinoma10.1038/s42255-022-00642-5 ↗
7. Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production10.1053/j.gastro.2020.12.015 ↗
8. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma10.1002/hep.27822 ↗
9. CTGF mediates tumor–stroma interactions between hepatoma cells and hepatic stellate cells to accelerate HCC progression10.1158/0008-5472.CAN-17-3844 ↗
10. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy10.1038/s41586-021-03614-z ↗
11. Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 - β-catenin cascade to promote liver tumorigenesis10.1038/s41467-023-38406-8 ↗
12. Hepatic stellate cells stimulate HCC cell migration via laminin-5 production10.1042/CS20110002 ↗
13. Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy10.1016/j.ejmech.2015.11.013 ↗
14. Hepatic stellate cells: partners in crime for liver metastases?10.1002/hep.24384 ↗
15. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets10.1038/s41392-020-00443-w ↗
16. YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer10.1186/s13046-017-0612-3 ↗
17. The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures10.1053/jhep.2002.31778 ↗
18. Prostaglandin E2 inhibits transforming growth factor β1-mediated induction of collagen α1(I) in hepatic stellate cells10.1016/j.jhep.2004.04.033 ↗
19. Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat10.1111/j.1478-3231.2010.02256.x ↗
20. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats10.1136/gut.2008.157420 ↗
21. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma10.1158/0008-5472.CAN-06-0325 ↗
22. Celecoxib-induced self-assembly of smart albumin-doxorubicin conjugate for enhanced cancer therapy10.1021/acsami.8b00875 ↗
23. Selective killing of cancer cells by nonplanar aromatic hydrocarbon-induced DNA damage10.1002/advs.201901341 ↗
24. Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis10.1038/s41401-023-01158-8 ↗
25. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition10.1016/j.actbio.2019.09.001 ↗
26. A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance10.1038/cdd.2017.176 ↗
27. Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance10.1038/s41467-020-20588-0 ↗
28. Hepatic stellate cells activated by acidic tumor microenvironment promote the metastasis of hepatocellular carcinoma via osteopontin10.1016/j.canlet.2014.10.021 ↗
29. Stepwise targeting and tandem responsive peptide nanoparticles enhance immunotherapy through prolonged drug retention10.1021/acsmaterialslett.3c00357 ↗
30. pH-triggered transformable peptide nanocarriers extend drug retention for breast cancer combination therapy10.1002/adhm.202400031 ↗
31. Morphologically transformable peptide nanocarriers coloaded with doxorubicin and curcumin inhibit the growth and metastasis of hepatocellular carcinoma, Mater
32. Natively unfolded nucleoporins gate protein diffusion across the nuclear pore complex10.1016/j.cell.2007.01.044 ↗
33. Incorporation of drug efflux inhibitor and chemotherapeutic agent into an inorganic/organic platform for the effective treatment of multidrug resistant breast cancer10.1186/s12951-019-0559-y ↗
34. Lectin-mediated pH-sensitive doxorubicin prodrug for pre-targeted chemotherapy of colorectal cancer with enhanced efficacy and reduced side effects10.7150/thno.29989 ↗
35. Caspase-cleaved arrestin-2 and BID cooperatively facilitate cytochrome C release and cell death10.1038/cdd.2013.143 ↗
36. The BCL-2 protein family, BH3-mimetics and cancer therapy10.1038/cdd.2015.50 ↗
37. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization10.1016/j.cell.2010.03.053 ↗
38. Neuropilin-2 is upregulated in lung cancer cells during TGF-β1–induced epithelial–mesenchymal transition10.1158/0008-5472.CAN-13-1755 ↗
39. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer10.1186/s13046-017-0655-5 ↗
40. TGF-β1 mediated activation of Rho kinase induces TGF-β2 and endothelin-1 expression in human hepatic stellate cells10.1016/j.jhep.2010.07.026 ↗
41. Wharton's jelly-derived mesenchymal stromal cells and fibroblast-derived extracellular matrix synergistically activate apoptosis in a p21-dependent mechanism in WHCO1 and MDA MB 231 cancer cells in vitro
42. Targeting apoptosis pathways by Celecoxib in cancer10.1016/j.canlet.2011.01.012 ↗
43. Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice10.1053/j.gastro.2015.07.064 ↗
44. Decoding cell death signals in liver inflammation10.1016/j.jhep.2013.03.033 ↗
45. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8+ T-cell-dependent antitumor immunity10.7150/thno.82182 ↗
46. Slow train coming: an anti-CCN2 strategy reverses a model of chronic overuse muscle fibrosis10.1007/s12079-020-00568-1 ↗
47. Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism10.1002/hep.24352 ↗